Superworth

Cryoport free cash flow CYRX

Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$20M
Latest quarter, Q2 FY26
−$8M
Fiscal year 2025
−$25M

Cryoport's free cash flow was −$20M over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$8M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$25Mn/a
FY2024−$33.6Mn/a
FY2023−$39.5Mn/a
FY2022−$24Mn/a
FY2021−$15.8Mn/a
FY2020−$23.8Mn/a
FY2019−$6.7Mn/a
FY2018−$6.3Mn/a
FY2017−$5.3Mn/a
FY2016−$7.4Mn/a
FY2016−$7Mn/a
FY2015−$4.2Mn/a
FY2014−$4.5Mn/a
FY2013−$4.9Mn/a
FY2012−$7Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$8Mn/a−$20M
Q1 FY26−$6.2Mn/a−$23.8M
Q4 FY25−$4.5Mn/a−$25M
Q3 FY25−$1.3Mn/a−$31.2M
Q2 FY25−$11.7Mn/a−$33.7M
Q1 FY25−$7.5Mn/a−$33.8M
Q4 FY24−$10.7Mn/a−$33.6M
Q3 FY24−$3.8Mn/a−$32M
Q2 FY24−$11.8Mn/a−$39.1M
Q1 FY24−$7.3Mn/a−$40M
Q4 FY23−$9.1Mn/a−$39.5M
Q3 FY23−$10.9Mn/a−$34.7M

Against its peers

Companies in Drug Manufacturers - General nearest Cryoport's size, closest first, today.

CompanyFree cash flow yield
CYRXCryoport−2.2%
ABUSArbutus Biopharman/m
AMPHAmphastar Pharmaceuticals14.3%
COLLCollegium Pharmaceuticaln/m
OMEROmeros−5.7%
CRMDCorMedixn/m
ZVRAZevra Therapeutics5.6%
IRWDIronwood Pharmaceuticalsn/m
PCRXPacira BioSciences12.4%
ANABAnaptysbion/m
PBYIPuma Biotechnology7.2%
Peer median7.2%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Cryoport

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.